Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Open Access
- 1 June 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 18 (6), 733-743
- https://doi.org/10.1634/theoncologist.2012-0483
Abstract
The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor-1 and programmed death receptor ligand-1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune-related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 54 references indexed in Scilit:
- Thyroid Dysfunction from Antineoplastic AgentsJNCI Journal of the National Cancer Institute, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical TrialClinical Cancer Research, 2010
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T CellsDigestive Diseases and Sciences, 2009
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationBlood, 2009
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Risk of Bowel Perforation in Patients Receiving Interleukin-2 After Therapy With Anti-CTLA 4 Monoclonal AntibodyJournal of Immunotherapy, 2007
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006